Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib in BRCA-mutated solid tumors
NCT05904730Phase 1Completed
- Sponsor
- Lynkcell
- Start
- Jul 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of axitinib in breast cancer, ovarian cancer and solid tumor, sponsored by Lynkcell. Primary endpoint: Antitumor effect of axitinib up to 90 days. Started Jul 2023; status: completed.
02
Drugs
axitinib
03
Conditions
breast cancerovarian cancersolid tumor
Beyond the preview
Go deeper on NCT05904730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05904730.